• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂肪性肝炎性肝细胞癌:一种新的肝细胞癌形态亚型分类方法。

Steatohepatitic hepatocellular Carcinoma:A new approach to classifying morphological subtypes of hepatocellular carcinoma.

机构信息

Department of Pathology, National University Hospital, Singapore.

Ospedale Pediatrico Bambino Gesu, 00165 Rome, Italy.

出版信息

Hum Pathol. 2024 Jul;149:55-65. doi: 10.1016/j.humpath.2024.06.007. Epub 2024 Jun 12.

DOI:10.1016/j.humpath.2024.06.007
PMID:38876199
Abstract

Histological subtyping of hepatocellular carcinoma (HCC) is challenging in the presence of histological heterogeneity, where distinctly different morphological patterns are present within the same tumor. Current approaches rely on percent cut-offs. We hypothesized that morphologic intratumor heterogeneity is a non-random biological feature and that incorporating recurrent patterns would improve histological subtyping of HCC. Resected HCC were studied and the overall frequency of morphologic intratumor heterogeneity was 45% in 242 specimens. Steatohepatitic HCC (SH-HCC) had the highest frequency of morphologic intratumor heterogeneity (91%); this was confirmed in additional cohorts of SH-HCC from different medical centers (overall frequency of 78% in SH-HCC). Morphologic intratumor heterogeneity in SH-HCC showed distinct and recurrent patterns that could be classified as early, intermediate, and advanced. Incorporating these patterns into the definition of SH-HCC allowed successful resolution of several persistent challenges: the problem of the best cut-off for subtyping SH-HCC, the problem of the relationship between SH-HCC and scirrhous HCC, and the classification for HCC with abundant microvesicular steatosis. This approach also clarified the relationship between SH-HCC and CTNNB1 mutations, showing that CTNNB1 mutations occur late in a subset of SH-HCC. In summary, there is a high frequency of morphologic intratumor heterogeneity in HCC. Incorporating this finding into histological subtyping resolved several persistent problems with the SH-HCC subtype.

摘要

肝细胞癌 (HCC) 的组织学亚型分类具有挑战性,因为在同一肿瘤中存在明显不同的形态模式,存在组织学异质性。目前的方法依赖于百分比截断值。我们假设形态学肿瘤内异质性是非随机的生物学特征,并且纳入反复出现的模式将改善 HCC 的组织学亚型分类。研究了切除的 HCC,在 242 个标本中,形态学肿瘤内异质性的总体频率为 45%。脂肪性肝炎相关 HCC (SH-HCC) 的形态学肿瘤内异质性频率最高(91%);这在来自不同医疗中心的额外 SH-HCC 队列中得到了证实(SH-HCC 的总体频率为 78%)。SH-HCC 中的形态学肿瘤内异质性表现出明显且反复出现的模式,可以分为早期、中期和晚期。将这些模式纳入 SH-HCC 的定义中,成功解决了几个持续存在的挑战:SH-HCC 亚型分类的最佳截断值问题、SH-HCC 与硬癌性 HCC 之间关系的问题以及富含微泡脂肪变性的 HCC 的分类问题。这种方法还澄清了 SH-HCC 与 CTNNB1 突变之间的关系,表明 CTNNB1 突变发生在 SH-HCC 的一部分中较晚。总之,HCC 中存在较高频率的形态学肿瘤内异质性。将这一发现纳入组织学亚型分类中,解决了 SH-HCC 亚型的几个持续存在的问题。

相似文献

1
Steatohepatitic hepatocellular Carcinoma:A new approach to classifying morphological subtypes of hepatocellular carcinoma.脂肪性肝炎性肝细胞癌:一种新的肝细胞癌形态亚型分类方法。
Hum Pathol. 2024 Jul;149:55-65. doi: 10.1016/j.humpath.2024.06.007. Epub 2024 Jun 12.
2
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗:系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
3
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
4
Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.对比增强超声在慢性肝病成人肝细胞癌诊断中的应用。
Cochrane Database Syst Rev. 2022 Sep 2;9(9):CD013483. doi: 10.1002/14651858.CD013483.pub2.
5
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
6
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
7
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.肝细胞癌肝硬化监测:系统评价与经济分析
Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
10
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.系统治疗不可切除肝细胞癌的序贯治疗:随机临床试验的系统评价和贝叶斯网络荟萃分析。
Crit Rev Oncol Hematol. 2024 Dec;204:104522. doi: 10.1016/j.critrevonc.2024.104522. Epub 2024 Sep 26.

本文引用的文献

1
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.多组学鉴定了肝细胞癌肿瘤内脂肪变性与耗竭性肿瘤免疫微环境之间的联系。
Hepatology. 2023 Jan 1;77(1):77-91. doi: 10.1002/hep.32573. Epub 2022 Jun 17.
2
Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.β-连环蛋白突变型肝细胞癌的形态学异质性:对肿瘤分子分类的影响。
Hum Pathol. 2022 Jan;119:15-27. doi: 10.1016/j.humpath.2021.09.009. Epub 2021 Sep 27.
3
Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes.
肝细胞癌:解析形态异质性、生长模式和亚型。
Hum Pathol. 2021 Jun;112:86-101. doi: 10.1016/j.humpath.2020.12.009. Epub 2020 Dec 30.
4
New Names for Old Tumors.旧肿瘤的新命名。
Am J Clin Pathol. 2021 Apr 26;155(5):698-710. doi: 10.1093/ajcp/aqaa184.
5
Metabolic reprogramming and cancer progression.代谢重编程与癌症进展。
Science. 2020 Apr 10;368(6487). doi: 10.1126/science.aaw5473.
6
Pathology of liver disease: advances in the last 50 years.肝脏疾病病理学:过去 50 年的进展。
Hum Pathol. 2020 Jan;95:78-98. doi: 10.1016/j.humpath.2019.08.023. Epub 2019 Sep 4.
7
Mechanisms and Implications of Metabolic Heterogeneity in Cancer.癌症代谢异质性的机制与意义。
Cell Metab. 2019 Sep 3;30(3):434-446. doi: 10.1016/j.cmet.2019.08.013.
8
Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features.脂肪变性和非脂肪变性硬癌型肝细胞癌具有不同的临床病理特征。
Hum Pathol. 2019 Apr;86:222-232. doi: 10.1016/j.humpath.2018.11.024. Epub 2018 Dec 28.
9
The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.G1-G6 转录组特征和 5 基因评分在韩国肝细胞癌患者中的临床意义。
BMC Cancer. 2018 May 18;18(1):571. doi: 10.1186/s12885-018-4192-1.
10
Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.在肝细胞癌中,主干突变事件表现出最小的肿瘤内和肿瘤间异质性。
J Hepatol. 2017 Dec;67(6):1222-1231. doi: 10.1016/j.jhep.2017.08.013. Epub 2017 Aug 24.